NEW YORK, May 28, 2015 (GLOBE NEWSWIRE) -- Morgan & Morgan reminds investors that a shareholder class action has been filed against Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) ("Aerie" or the "Company") on behalf of purchasers of the Company's common stock between August 6, 2014 and April 23, 2015, inclusive (the "Class Period").
If you purchased Aerie common stock during the Class Period, you may, no later than June 29, 2015, request that the Court appoint you lead plaintiff of the proposed class. A lead plaintiff is a representative party that acts on behalf of all class members in directing the litigation. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you want more information about the Aerie Pharmaceuticals, Inc. Securities Class Action, contact Morgan & Morgan at 1(800) 732-5200 or email info@morgansecuritieslaw.com.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.
The complaint alleges that, throughout the Class Period, Aerie and certain of its executive officers made a series of false and misleading statements and/or failed to disclose material adverse information about the future prospects for Rhopressa, a once-daily eye drop that is designed to lower intraocular pressure ("IOP") in patients with glaucoma or ocular hypertension.
On April 23, 2015, Aerie issued a press release announcing the results of its first Phase 3 registration trial for Rhopressa. According to the press release, "[t]he trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma." Following this news, shares of Aerie's stock fell $22.52 per share, or over 63 percent, to close on April 24, 2015 at $12.87 per share.
About Morgan & Morgan
Morgan & Morgan is one of the nation's largest 200 law firms. In addition to shareholder rights, the firm also practices in the areas of antitrust, personal injury, consumer protection, overtime, and product liability. All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people."
Attorney advertising. Prior results do not guarantee a similar outcome.